pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,016 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1786Endpoints1391Fierce Biotech710BioSpace701BioPharma Dive525raps234onclive165fda recalls113fda medwatch
therapy area
allOncology12335Rare Disease3224Immunology2872Cardiology2751Hematology2177Pulmonology2149Vaccines
  • Swiss pharma manufacturing remains steady despite tariff threats, impact may take years
    Swiss biotech day event highlighted that pharma manufacturing in Switzerland shows no immediate disruption from geopolitical tensions or potential tariffs. Industry representatives said that while…
    Endpoints · 6mo agoNeutral↗ source
  • Healthcare giants increasingly develop in-house AI tools instead of buying from startups
    Panelists at the Digital Healthcare Innovation Summit in Boston highlighted a growing shift among large health‑care organizations toward creating their own artificial‑intelligence solutions. Rather…
    Endpoints · 6mo agoNeutral↗ source
← prev
page 116 of 121
next →
111
globenewswire health73
fda press59
1802
Psychiatry & CNS1204
Ophthalmology1062
Pain778
Endocrinology & Metabolism777
Nephrology760
JAK inhibitor sequencing and transplant timing in myelofibrosis discussed at 2026 conference
Dr. Andrew Kuykendall of Moffitt Cancer Center explained how doctors decide the order of JAK inhibitor therapies and when to consider allogeneic stem cell transplant for myelofibrosis patients. At…
onclive · 6mo agoNeutral↗ source
  • Experts Highlight Emerging Strategies and Unmet Needs in Mantle Cell Lymphoma
    Dr. Lore Gruenbaum, PhD, recently discussed the evolving landscape of mantle cell lymphoma (MCL) in a presentation titled “New Understandings of Treatments, End Points, and Disease Biology Expand M…
    onclive · 6mo agoNeutral↗ source
  • Simlukafusp Alfa plus atezolizumab shows safety but no benefit over standard care in metastatic kidney cancer
    A clinical study evaluated the novel immunocytokine simlukafusp alfa combined with atezolizumab, with or without bevacizumab, in patients with unresectable metastatic renal cell carcinoma. The com…
    onclive · 6mo agoNegative readoutNeutral↗ source
  • Intercept’s next-generation FXR agonist INT-787 fails Phase 2 trial in alcohol-associated hepatitis
    Intercept Pharmaceuticals reported that its experimental FXR agonist INT-787 did not demonstrate efficacy in a Phase 2 study of patients with severe alcohol-associated hepatitis. The trial results…
    Endpoints · 6mo agoNegative readoutNegative↗ source
  • Study links specific dietary fats to pancreatic cancer risk, highlighting oleic acid as promoter and omega-3s as protective
    Researchers at Yale Cancer Center examined how different types of dietary fat affect pancreatic cancer development in a mouse model. Rather than focusing on total fat intake, the study compared twe…
    onclive · 6mo agoNeutral↗ source
  • Experts stress seamless coordination for relapsed multiple myeloma patients across academic and community clinics
    In a recent opinion segment, Dr. Ajay K. Nooka convened a discussion with Dr. Noopur S. Raje and Dr. Surbhi Sidana about how to best coordinate care for patients with relapsed and refractory multip…
    onclive · 6mo agoNeutral↗ source
  • Patient with EGFR-mutated NSCLC develops brain metastases after first-line EGFR inhibitor and chemotherapy
    Dr. Sands presented a case of a patient with metastatic non-small cell lung cancer that carries an EGFR mutation. The patient was treated with a first-line regimen that combined an EGFR tyrosine k…
    onclive · 6mo agoNeutral↗ source
  • Celcuity reports positive Phase 3 results for gedatolisib in PIK3CA-mutant breast cancer
    On May 4, 2026 Celcuity announced that its experimental drug gedatolisib achieved success in two treatment regimens for patients whose tumors carry PIK3CA mutations, according to data from its ongo…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • Latus Bio raises $97 million to advance gene therapies for Huntington’s and Batten disease
    Latus Bio announced closing a $97 million Series A round, including a $43 million extension to a prior $54 million raise. Funding was led by 8VC and included eight other investors such as DCVC Bio…
    BioPharma Dive · 6mo agoDealPositive↗ source
  • UCB to buy Candid Therapeutics for up to $2.2 billion, targeting bispecific antibodies for autoimmune disease
    UCB announced a deal to acquire Candid Therapeutics, a startup focused on bispecific antibody drugs, for an upfront payment of $2 billion with up to $200 million in future milestones. The transacti…
    BioPharma Dive · 6mo agoDealPositive↗ source
  • UCB commits $2 billion to Candid's T cell engager program for autoimmune diseases
    UCB, a long standing European pharmaceutical company, announced a $2 billion investment in Candid, a biotech focused on T cell engager therapies aimed at autoimmune conditions. The deal reflects U…
    Endpoints · 6mo agoDealPositive↗ source
  • Celcuity reports positive Phase 3 data for gedatolisib, bolstering broader approval prospects
    Celcuity announced new data from an ongoing Phase 3 trial of its experimental breast cancer drug gedatolisib. The data showed that two- and three-drug combinations that included gedatolisib delaye…
    BioPharma Dive · 6mo agoPositive readoutPositive↗ source
  • Supreme Court reverses stay, allowing mail ordering of abortion pill mifepristone
    The U.S. Supreme Court issued a decision on Monday that restores the ability to order the abortion medication mifepristone by mail. This action overturns a stay that had been placed by a federal ap…
    Endpoints · 6mo agoRegulatoryPositive↗ source
  • Swiss biotech Windward Bio raises $165 million to launch Phase 3 asthma trial for China-derived drug
    Swiss biotech Windward Bio announced it has secured $165 million in financing. The capital will be used to move one of its two experimental medicines, originally discovered in China, into a Phase…
    Endpoints · 6mo agoDealPositive↗ source
  • AI drug repurposing in oncology hampered by fragmented data, curated knowledge needed
    AI tools are being used to look for new cancer indications for existing biologics, but the article notes that fragmented and disparate data sets limit even the most advanced models. Repurposing pr…
    BioPharma Dive · 6mo agoNeutral↗ source
  • Vertex halts mRNA cystic fibrosis program citing tolerability concerns
    Vertex Pharmaceuticals announced it is ending development of its mRNA-based cystic fibrosis therapy after encountering tolerability problems that echo challenges seen elsewhere in the field. The B…
    Endpoints · 6mo agoNegative↗ source
  • FDA narrows search for new CBER chief to three or four finalists
    The FDA announced that its search for a new head of the Center for Biologics Evaluation and Research (CBER) has been narrowed. According to a source familiar with the process, the agency is now fo…
    Endpoints · 6mo agoRegulatoryNeutral↗ source
  • Biotech sees rise of lean startups backed by large funding and Chinese assets
    A new wave of biotech companies is emerging that prioritises lean organizational structures over extensive early‑stage research programs. These firms are being launched with modest employee counts…
    Endpoints · 6mo agoNeutral↗ source
  • Bristol Myers faces pivotal year as Q1 earnings season begins
    The weekly Endpoints newsletter for the last week of April highlighted that several pharmaceutical companies released their first-quarter earnings. Among them, Bristol Myers was singled out as bei…
    Endpoints · 6mo agoEarningsNeutral↗ source
  • Bristol Myers shows modest revenue rise, Biogen beats forecasts, Regeneron outlook remains uncertain
    BioPharma Dive highlighted the latest quarterly earnings from three major biotech firms, noting how investors are interpreting the results. Bristol Myers Squibb reported $11.5 billion in revenue f…
    BioPharma Dive · 6mo agoEarningsNeutral↗ source
  • FDA approves Arvinas' PROTAC drug Veppanu for specific metastatic breast cancer
    U.S. regulators have granted approval for Veppanu, a protein-degrading therapy developed by biotech firm Arvinas, to treat a defined group of patients with metastatic, estrogen-receptor-positive, H…
    BioPharma Dive · 6mo agoApprovalPositive↗ source
  • Summit Therapeutics' ivonescimab misses interim goal, shares tumble 27% as trial setback raises doubts
    Summit Therapeutics reported that its experimental immunotherapy ivonescimab failed to achieve statistical significance at an interim analysis of the late-stage HARMONi-3 trial in frontline non‑sma…
    BioPharma Dive · 6mo agoNegative readoutNegative↗ source
  • FDA approves Axsome Therapeutics' Auvelity for Alzheimer’s agitation
    The U.S. Food and Drug Administration has granted approval to Axsome Therapeutics’ oral medication Auvelity for the treatment of agitation in patients with Alzheimer’s disease. Axsome noted that a…
    Endpoints · 6mo agoApprovalPositive↗ source